| Intrinsic Valuation of: AMBUJACEM | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2021 | - | - | EPS (FY) | 19 | Market Cap | ₹1,078B | |||||
| 2022 | ₹-54B | - (-) | P/E Ratio | 23 | Total Asset | ₹896B | |||||
| 2023 | ₹30B | 155.2 (159.9) | Net Income | ₹47B | Total Debt | ₹448M | |||||
| 2024 | ₹12B | -60.9% (-65.7%) | EBITDA | ₹71B | Total Liab | ₹178B | |||||
| 2025 | ₹-64B | -654.4% (-630.6%) | Opr Margin | 7.34 | Debt/Equity | 0.00 | |||||
| 2026 | ₹-10B | 84.8% (87.2%) | PreTax Margin | 6.79 | BV/Share | 146 | |||||
| 5Y Average FCF | ₹-17B | 3.5% (-203.0%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.00% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (3.5%) | ||||||||||
| 2027 | ₹21B | MBG Intrinsic Value | ₹170 | ||||||||
| 2028 | ₹22B | ||||||||||
| 2029 | ₹23B | ||||||||||
| 2030 | ₹23B | ||||||||||
| 2031 | ₹24B | ||||||||||
| 2032 | ₹25B | ||||||||||
| Terminal Value | ₹559B | Net Worth/Share | ₹289 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹482B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹9B | ₹197 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹448M | WACC | 6.5% | 186 | 202 | 222 | 247 | 281 | |||
| Equity Value | ₹491B | 7.1% | 165 | 177 | 192 | 210 | 234 | ||||
| Shares Outstanding | 2,484,817,186 | 7.8% | 149 | 159 | 170 | 183 | 200 | ||||
| 8.4% | 136 | 143 | 152 | 162 | 175 | ||||||
| DCF Intrinsic Value | ₹197 | 9.0% | 125 | 131 | 138 | 146 | 156 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||